Table 4 |
||||||
|
Statistical comparison on the performance of the 3 methods used |
||||||
|
specificity |
Sensitivity a) |
PPV |
NPV |
|||
|
|
||||||
|
Antigenemia pp65 |
67% |
80% |
63% |
49% |
||
|
globally |
CMV Monitor |
63% |
90% |
69% |
57% |
|
|
Without |
pp67 mRNA b) |
76% |
85% |
88% |
58% |
|
|
|
||||||
|
cut-off |
Antigenemia pp65 |
62% |
- |
30% |
73% |
|
|
Before |
||||||
|
CMV Monitor |
64% |
- |
28% |
74% |
||
|
treatment |
||||||
|
pp67 mRNA b) |
79% |
- |
60% |
76% |
||
|
|
||||||
|
Antigenemia pp65 |
93% |
65% |
94% |
54% |
||
|
globally |
CMV Monitor |
86% |
90% |
89% |
59% |
|
|
With |
pp67 mRNA b) |
- |
- |
- |
- |
|
|
|
||||||
|
cut-off |
Antigenemia pp65 |
91% |
- |
80% |
77% |
|
|
Before |
||||||
|
CMV Monitor |
87% |
- |
57% |
78% |
||
|
treatment |
||||||
|
pp67 mRNA b) |
- |
- |
- |
- |
||
|
|
||||||
|
a) No determinations were available before beginning of treatment since this variable requires a disease event b) No cut-off value could be used due to the method's qualitative nature |
||||||
|
Amorim et al. BMC Infectious Diseases 2001 1:2 doi:10.1186/1471-2334-1-2 |
||||||
